Moderna COVID-19 Vaccine: Booster Study Hits Only One Of Two Immunogenicity Endpoints

 
• By Sue Sutter
  
Bullseye hit and miss
Moderna's vaccine booster trial hit the target on one immunogenicity endpoint but missed on the other. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers